EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance of Colorimetric Lateral Flow Immunoassays for Renal Function Evaluation with Human Serum Cystatin C

Xushuo Zhang iD, Sam Fishlock iD, Peter Sharpe iD, James McLaughlin iD

Biosensors · 11.07.2025 · 15 (7) · 445

DOI: 10.3390/bios15070445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors, online erschienen am 11.07.2025. Verfasst von Xushuo Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nanotechnology Integrated Bioengineering Centre (NIBEC), Ulster University, Shore Road, Newtownabbey, County Antrim BT37 0QB, UK. Hauptthemen laut MEDLINE: Cystatin C, Colorimetry, Kidney Function Tests, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INTERREG VA program, European Union’s INTERREG VA program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is associated with heart failure and neurological disorders. Therefore, point-of-care (POC) detection of CKD is essential, allowing disease monitoring from home and alleviating healthcare professionals’ workload. Lateral flow immunoassays (LFIAs) facilitate POC testing for a renal function biomarker, serum Cystatin C (CysC). LF devices were fabricated and optimised by varying the diluted sample volume, the nitrocellulose (NC) membrane, bed volume, AuNPs’ OD value and volume, and assay formats of partial or full LF systems. Notably, 310 samples were analysed to satisfy the minimum sample size for statistical calculations. This allowed for a comparison between the LFIAs’ results and the general Roche standard assay results from the Southern Health and Social Care Trust. Bland–Altman plots indicated the LFIAs measured 0.51 mg/L lower than the Roche assays. With the 95% confidence interval, the Roche method might be 0.24 mg/L below the LFIAs’ results or 1.27 mg/L above the LFIAs’ results. In summary, the developed non-fluorescent LFIAs could detect clinical CysC values in agreement with Roche assays. Even though the developed LFIA had an increased bias in low CysC concentration (below 2 mg/L) detection, the developed LFIA can still alert patients at the early stages of renal function impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystatin CColorimetryKidney Function TestsRenal Insufficiency, ChronicHumansImmunoassayBiomarkers

Stichwörter der Autor:innen

gold nanoparticleslateral flow immunoassaypoint-of-careserum Cystatin C

Substanzen

Cystatin CBiomarkers

Autor:innen und Institutionen

  • Nanotechnology Integrated Bioengineering Centre (NIBEC), Ulster University, Shore Road, Newtownabbey, County Antrim BT37 0QB, UK.
  • Southern Health & Social Care Trust (SHSCT), Craigavon Area Hospital, 68 Lurgan Road, Portadown BT63 5QQ, UK.

ORCID-Profile: Xushuo Zhang, Sam Fishlock, Peter Sharpe, James McLaughlin

Förderung

  • INTERREG VA program
  • European Union’s INTERREG VA program

Zitieren

APA

Zhang, X., Fishlock, S., Sharpe, P., & McLaughlin, J. (2025). Performance of Colorimetric Lateral Flow Immunoassays for Renal Function Evaluation with Human Serum Cystatin C. Biosensors, 15(7), 445. https://doi.org/10.3390/bios15070445

Vancouver

Zhang X, Fishlock S, Sharpe P, McLaughlin J. Performance of Colorimetric Lateral Flow Immunoassays for Renal Function Evaluation with Human Serum Cystatin C. Biosensors. 2025;15(7):445. doi:10.3390/bios15070445

BibTeX
@article{Zhang2025,
  author = {Zhang, Xushuo and Fishlock, Sam and Sharpe, Peter and McLaughlin, James},
  title = {Performance of Colorimetric Lateral Flow Immunoassays for Renal Function Evaluation with Human Serum Cystatin C},
  journal = {Biosensors},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {445},
  doi = {10.3390/bios15070445}
}
Kostenlos starten →